← Back to Search

Monoclonal Antibodies

Lutikizumab for Hidradenitis Suppurativa

Phase 3
Recruiting
Research Sponsored by AbbVie
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
At least 1 anatomic area of HS involvement characterized as Hurley Stage II or higher at Baseline.
Hidradenitis suppurativa (HS) lesions present in at least two distinct anatomic areas at Baseline.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to approximately week 62
Awards & highlights

Summary

This trial is testing a new drug called lutikizumab for the treatment of a skin condition called Hidradenitis suppurativa (HS), which causes painful lumps and abscess

Who is the study for?
This trial is for adults and adolescents with moderate to severe Hidradenitis Suppurativa (HS), a painful skin condition. Participants must have been diagnosed at least 6 months ago, have five or more abscesses or nodules, and HS lesions in two areas of the body, one being at least Hurley Stage II.
What is being tested?
The study tests Lutikizumab against a placebo in treating HS. Initially, participants are randomly assigned to receive either Lutikizumab or placebo injections weekly for 16 weeks. Afterwards, they may continue with different dosing schedules of Lutikizumab for up to 36 weeks.
What are the potential side effects?
Potential side effects include reactions at the injection site, increased risk of infections due to immune system suppression by Lutikizumab, headaches, nausea and potential unknown risks as it's an investigational drug.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My HS condition is at least at a moderate severity stage.
Select...
I have HS lesions in two or more separate areas.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to approximately week 62
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to approximately week 62 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants with Adverse Events (AEs)
Percentage of Participants Achieving Hidradenitis Suppurative Clinical Response (HiSCR) 75
Secondary outcome measures
Change from Baseline in Dermatology Life Quality Index (DLQI)
Change from Baseline in HSSA
Change from Baseline in Hidradenitis Suppurativa Impact Assessment (HSIA)
+5 more

Trial Design

6Treatment groups
Experimental Treatment
Group I: Period 2: Placebo to Lutikizumab Group Every WeekExperimental Treatment1 Intervention
Participants that were assigned Placebo in Period 1 and initiated lutikizumab in Period 2 will then be re-randomized to lutikizumab Dose A every week through Week 52
Group II: Period 2: Placebo to Lutikizumab Group Every Other WeekExperimental Treatment2 Interventions
The participants that were assigned Placebo in Period 1 and initiated lutikizumab in Period 2 will then be re-randomized to lutikizumab Dose A every other week through Week 52
Group III: Period 2: Placebo to Lutikizumab GroupExperimental Treatment1 Intervention
Participants randomized to Placebo in Period 1 who complete Week 16 of the study will initiate lutikizumab with Dose B followed by Dose A every week.
Group IV: Period 2: Lutikizumab Every WeekExperimental Treatment1 Intervention
Participants randomized to lutikizumab in Period 1 who complete Week 16 of the study will be re-randomized to lutikizumab Dose A through Week 52
Group V: Period 2: Lutikizumab Every Other WeekExperimental Treatment2 Interventions
Participants randomized to lutikizumab in Period 1 who complete Week 16 of the study will be re-randomized to lutikizumab Dose A every other week though week 52
Group VI: Period 1Experimental Treatment2 Interventions
Participants will be randomized to either Lutikizumab Dose B at baseline followed by Lutikizumab Dose A, or a matching placebo dose equivalent for both, every week through Week 16 .
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Placebo
1995
Completed Phase 3
~2670

Find a Location

Who is running the clinical trial?

AbbVieLead Sponsor
1,004 Previous Clinical Trials
512,498 Total Patients Enrolled
13 Trials studying Hidradenitis Suppurativa
3,008 Patients Enrolled for Hidradenitis Suppurativa
ABBVIE INC.Study DirectorAbbVie
430 Previous Clinical Trials
154,818 Total Patients Enrolled
6 Trials studying Hidradenitis Suppurativa
1,945 Patients Enrolled for Hidradenitis Suppurativa
~853 spots leftby Dec 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top